RDiscovery — Full Portfolio

Capacity Bio is a biotechnology company developing mitophagy modulators — small molecules, peptides, and nanoparticles that target mitochondrial biology to identify and clear dysfunctional mitochondria.

BiotechDeep TechLongevityPalo Alto, US

Amy Wang(PhD)Kenneth Horne(Executive Officer, Director)inDylan Morris(Director)Cristina Ghenoiu(Director)

BoardTaro Inaba(Director)inKen Horne

Co-investorsRemiges Ventures, Inc.Insight PartnersRA CapitalAN Venture Partners

Develops cell-based therapies to restore mitochondrial function for treatment of genetic diseases and age-related indications.

Imel Biotherapeutics is a biotech company focused on mitochondrial biology, targeting mitochondrial dysfunction implicated in aging, cellular senescence, and T cell exhaustion in the elderly population.

BiotechLongevity

Co-investorsPontifax Venture Capital

NapaJen Pharma is a biopharmaceutical research and development company developing nucleic acid (oligonucleotide) drugs using a proprietary cell-specific drug delivery platform that enables delivery to immune cells for precision-targeted immunosuppression and controlled immuno-stimulation.

BiotechDeep TechMedical DevicesSeattle, US

有馬賢治(CEO & Director (NapaJen Pharma, Inc.); Representative Director (NapaJen Pharma K.K.))

Co-investorsRemiges Ventures, Inc.

Venture capital-led drug discovery startup focused on Sensory Medicine, developing pharmaceutical interventions based on sensory stimulation and artificial hibernation concepts.

Myrodia Therapeutics is a Japanese biopharmaceutical company developing drug candidates based on its "sensory drug discovery" concept, which uses sensory stimuli to induce artificial hibernation and protective physiological states.

BiotechDeep TechHealthtech

小早川 高(CSO / Founder)小早川 令子(Founder)神谷 勇輝(CEO / 代表取締役)水野 敦之(CFO)小林 実(COO)

Co-investorsRemiges Ventures, Inc.ANRI

Sanodyne Therapeutics develops SNT-001, an orally administered small-molecule compound intended to treat peripheral neuropathy and neuropathic pain.

BiotechDeep Tech

Co-investorsJIC Venture Growth Investments

Viage Therapeutics is a neuroscience drug developer working on novel oral neurotherapeutics that target the gut-brain axis, including its lead clinical candidate DGX-001 for cognitive impairment in conditions such as Alzheimer's and Parkinson's disease.

BiotechDeep TechHealthtechSan Francisco Bay Area, US

Titus Plattel(Leadership Team)inBrian Rogers(Leadership Team)inNeil Schwartz(Leadership Team)inSujata Sankar(Leadership Team)inSteven King(Leadership Team)in

Co-investorsKyoto University Innovation CapitalMiyako CapitalRemiges Ventures, Inc.